Martinez-Martin Pablo, Prieto Luis, Forjaz Maria João
Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Value Health. 2006 Nov-Dec;9(6):386-93. doi: 10.1111/j.1524-4733.2006.00131.x.
This study analyzes the longitudinal metric attributes of three Parkinson's disease (PD) disability scales, taking Hoehn and Yahr (HY) staging as the reference measure of PD progression.
A sample of 87 PD patients was assessed during regular medical visits, using the HY, the Unified Parkinson's Disease Rating Scale--Activities of Daily Living Section (UPDRS-ADL), the Schwab and England Scale (SES), and the Intermediate Scale for Assessment of PD (ISAPD), across a follow-up period of 2.6 +/- 1.0 years.
The following cross-sectional attributes were analyzed, at baseline and again on conclusion of the study: floor and ceiling effects, convergent validity, reliability, and standard error of measurement, all of which were found to be adequate. Longitudinal reproducibility values (intraclass correlation coefficient) were 0.81 (ISAPD) to 0.84 (UPDRS-ADL). Insofar as longitudinal validity was concerned, the change scores of the three disability scales correlated significantly with the HY change score, absolute value r = 0.33 to 0.45, P < 0.003. Slightly lower values were found when taking the annual rate of change, absolute value r = 0.20 to 0.36. The three scales were acceptable, even though there were small differences among them. The "minimal clinically important difference" proposed for these scales is: SES, -6; UPDRS-ADL, +2; ISAPD, +1.5 points.
The three scales proved adequate for longitudinal assessment of PD disability. UPDRS-ADL was more precise and ISAPD more consistent. Magnitude of change and correlation with change in HY were slightly higher with the ISAPD. Effect size and standardized response mean for the minimal change in HY were higher for the UPDRS-ADL.
本研究以霍恩和雅尔(HY)分期作为帕金森病(PD)进展的参考指标,分析三种帕金森病残疾评定量表的纵向度量属性。
选取87例PD患者作为样本,在定期就诊期间,使用HY量表、统一帕金森病评定量表-日常生活活动部分(UPDRS-ADL)、施瓦布和英格兰量表(SES)以及帕金森病评估中间量表(ISAPD)进行评估,随访时间为2.6±1.0年。
在基线和研究结束时分析了以下横断面属性:地板效应和天花板效应、收敛效度、信度以及测量标准误差,结果均显示良好。纵向再现性值(组内相关系数)为0.81(ISAPD)至0.84(UPDRS-ADL)。就纵向效度而言,三种残疾评定量表的变化分数与HY变化分数显著相关,绝对值r = 0.33至0.45,P < 0.003。以年变化率计算时,相关值略低,绝对值r = 0.20至0.36。尽管三种量表之间存在细微差异,但均可接受。这些量表的“最小临床重要差异”建议值为:SES,-6;UPDRS-ADL,+2;ISAPD,+1.5分。
这三种量表被证明适用于PD残疾的纵向评估。UPDRS-ADL更精确,ISAPD更具一致性。ISAPD在变化幅度和与HY变化的相关性方面略高。UPDRS-ADL在HY最小变化的效应量和标准化反应均值方面更高。